#1 Clinical Trials Search in Europe

Irinotecan

Irinotecan, also known as CPT-11 or Camptosar, is a chemotherapy drug being studied in various clinical trials for its effectiveness in treating different types of cancer. These trials aim to determine optimal dosing, evaluate its efficacy when combined with other treatments, and assess its potential in addressing advanced stages of cancer, particularly colorectal cancer and other solid tumors.

Table of Contents

What is Irinotecan?

Irinotecan is a chemotherapy drug used to treat various types of cancer. It is also known by several other names, including CPT-11, Camptosar, and Campto[1]. Irinotecan belongs to a class of drugs called topoisomerase I inhibitors, which work by interfering with the DNA in cancer cells, preventing them from dividing and growing[2].

What Conditions Does Irinotecan Treat?

Irinotecan is primarily used to treat the following conditions:

  • Metastatic Colorectal Cancer: This is cancer that has spread from the colon or rectum to other parts of the body. Irinotecan is commonly used as a treatment for this condition[1][3].
  • Advanced Solid Tumors: Irinotecan may be used in clinical trials to treat various types of advanced solid tumors[2].
  • Non-small Cell Lung Cancer: Some studies have explored the use of irinotecan in treating certain types of lung cancer[4].
  • Glioblastoma: This is an aggressive type of brain cancer. Irinotecan has been studied in combination with other drugs for treating recurrent glioblastoma[5].

How is Irinotecan Administered?

Irinotecan is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency can vary depending on the specific treatment plan, but some common administration methods include:

  • 90-minute intravenous infusion every two weeks[1]
  • 60-minute intravenous infusion every two weeks[6]
  • 30-minute intravenous infusion weekly for several weeks[5]

The exact dosage is usually calculated based on the patient’s body surface area (measured in mg/m²) and may be adjusted depending on how well the patient tolerates the treatment.

Irinotecan Combination Therapies

Irinotecan is often used in combination with other drugs to enhance its effectiveness. Some common combination therapies include:

  • FOLFIRI: This regimen combines irinotecan with fluorouracil (5-FU) and leucovorin. It is commonly used in treating metastatic colorectal cancer[7].
  • FOLFOXIRI: This intensive regimen combines irinotecan with oxaliplatin, fluorouracil, and leucovorin. It may be used in combination with targeted therapies like bevacizumab for metastatic colorectal cancer[8].
  • Irinotecan + Cetuximab: This combination has been studied for treating metastatic colorectal cancer, especially in patients whose cancer has specific genetic characteristics (KRAS and NRAS wild-type)[3].
  • Irinotecan + Capecitabine + Bevacizumab: This three-drug combination has been studied for metastatic colorectal cancer[9].

Potential Side Effects

Like all chemotherapy drugs, irinotecan can cause side effects. Some potential side effects include:

  • Diarrhea: This is a common side effect that can be severe in some cases[5].
  • Nausea and vomiting
  • Decreased blood cell counts: This can lead to an increased risk of infection, anemia, or bleeding[5].
  • Fatigue
  • Hair loss

Your healthcare team will monitor you closely for these and other side effects and may adjust your treatment if necessary.

Ongoing Research and Clinical Trials

Researchers continue to study irinotecan to find new ways to use it effectively and to understand how it interacts with other drugs. Some areas of ongoing research include:

  • Using irinotecan in combination with newer targeted therapies[1][3]
  • Exploring different dosing schedules to improve efficacy and reduce side effects[9]
  • Investigating the use of irinotecan in treating other types of cancer[4]
  • Studying how genetic factors might influence a patient’s response to irinotecan[4]

If you’re interested in participating in a clinical trial involving irinotecan, discuss this option with your oncologist. They can help you understand if any current trials might be suitable for your specific situation.

Aspect Details
Cancer Types Studied Colorectal cancer, malignant glioma, cervical cancer, sarcomas, solid tumors
Administration Methods Intravenous infusion, often in cycles with rest periods
Combination Therapies Often combined with other drugs like 5-fluorouracil, leucovorin, cisplatin
Dosage Considerations Dosage may be adjusted based on UGT1A1 genotype, exploring reduced doses for certain genetic profiles
Primary Outcomes Studied Tumor response rates, progression-free survival, overall survival, toxicity profiles
Common Side Effects Diarrhea, neutropenia, nausea, vomiting
Unique Aspects Exploration of liposomal formulations, personalized dosing based on genetics

FAQ

  • What is Irinotecan and how does it work? Irinotecan is a chemotherapy drug that fights cancer by interfering with the cancer cells' ability to divide and grow. It works by inhibiting an enzyme called topoisomerase I, which is important for DNA replication in cancer cells.
  • What types of cancer is Irinotecan being studied for? Irinotecan is being studied for various types of cancer, including colorectal cancer, malignant glioma (a type of brain tumor), cervical cancer, sarcomas, and other solid tumors.
  • How is Irinotecan typically administered in clinical trials? In clinical trials, Irinotecan is usually administered intravenously (through a vein). The dosage and frequency can vary depending on the specific trial, but it's often given in cycles, with treatment days followed by rest periods.
  • What are some common side effects of Irinotecan? Common side effects of Irinotecan can include diarrhea, nausea, vomiting, and decreased white blood cell count (neutropenia). The severity of side effects can vary depending on the dosage and individual patient factors.
  • Are there any genetic factors that affect how Irinotecan works? Yes, genetic variations in an enzyme called UGT1A1 can affect how a person's body processes Irinotecan. Some clinical trials are studying how to adjust Irinotecan dosing based on a patient's UGT1A1 genotype to optimize treatment and reduce side effects.

Ongoing Clinical Trials on Irinotecan

  • Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Comparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Testing trifluridine, tipiracil and nanoliposomal irinotecan combination for patients with bile duct or gallbladder cancer after previous treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy Spain

  • Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Italy Spain

  • Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Ireland +4

  • Study on Cetuximab, Irinotecan, and Fluorouracil for First-Line Treatment in Patients with Advanced Colorectal Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Irinotecan: A chemotherapy drug that inhibits topoisomerase I, an enzyme involved in DNA replication. It's used to treat various types of cancer, especially colorectal cancer.
  • CPT-11: Another name for Irinotecan, often used in clinical and research settings.
  • Camptosar: The brand name for Irinotecan.
  • Topoisomerase I: An enzyme that helps in the process of DNA replication. Irinotecan works by inhibiting this enzyme in cancer cells.
  • FOLFIRI: A chemotherapy regimen that combines Irinotecan with other drugs, typically including 5-fluorouracil and leucovorin.
  • UGT1A1: An enzyme involved in metabolizing Irinotecan. Genetic variations in UGT1A1 can affect how a person responds to Irinotecan treatment.
  • Neutropenia: A decrease in white blood cells called neutrophils, which can be a side effect of chemotherapy and increase the risk of infections.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent increasing the dose of a drug in a clinical trial.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References

  1. https://clinicaltrials.gov/study/NCT01925274
  2. https://clinicaltrials.gov/study/NCT00002902
  3. https://clinicaltrials.gov/study/NCT02296203
  4. https://clinicaltrials.gov/study/NCT01654081
  5. https://clinicaltrials.gov/study/NCT01308632
  6. https://clinicaltrials.gov/study/NCT00336856
  7. https://clinicaltrials.gov/study/NCT02935764
  8. https://clinicaltrials.gov/study/NCT01163396
  9. https://clinicaltrials.gov/study/NCT00875771